BioCina

Executive Summary

BioCina is an Australian contract development and manufacturing organization (CDMO) providing end-to-end biologics services, including process development, cGMP clinical and commercial manufacturing of microbial products, plasmid DNA, mRNA, lipid nanoparticle (LNP) formulations, and sterile injectables. Operating FDA, EMA, and TGA-approved facilities in Adelaide and Perth, the company serves clients in vaccines, gene therapy, oncology, and infectious diseases. Founded in 2021, BioCina has rapidly established a client-centric model focused on on-time, in-full delivery and inspection-ready quality. With 200-500 employees, the company leverages its expertise in technology transfer, analytical development, and scale-up to support biologic programs from early-stage to commercial supply. As a private platform company, BioCina is well-positioned to capture growing demand for biologics manufacturing in the Asia-Pacific region.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new large-scale manufacturing contract with a top-20 pharma company60% success
• Q4 2026Completion of facility expansion or new cleanroom capacity in Adelaide70% success
• Q2 2026Regulatory approval or certification for mRNA/LNP manufacturing capabilities80% success